A Phase 1, Single Arm, Single Center Pilot Study of Medi4736, an Anti-Pdl1 Therapy, for Patients With Myelofibrosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2016 Status changed from not yet recruiting to recruiting.
- 23 Aug 2016 New trial record